Zota Health Care Valuation

Q: What is the Fair Price of ZOTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ZOTA (₹612.4) is trading above our estimate of [[fair value]] (₹4.97)

Is ZOTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZOTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ZOTA (₹612.4) is trading above our estimate of fair value (₹4.97)

Significantly Below Fair Value: ZOTA is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZOTA?

Key metric: As ZOTA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ZOTA. This is calculated by dividing ZOTA's market cap by their current revenue.
What is ZOTA's PS Ratio?
PS Ratio	7x
Sales	₹2.20b
Market Cap	₹15.41b

ZOTA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.5x
Enterprise Value/EBITDA	-116.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ZOTA's PS Ratio compare to its peers?

The above table shows the PS ratio for ZOTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.2x
SIGACHI Sigachi Industries	4x	n/a	₹17.8b
531633 Lincoln Pharmaceuticals	3x	n/a	₹18.1b
541096 Bharat Parenterals	3.8x	n/a	₹11.3b
506260 Anuh Pharma	1.7x	n/a	₹10.8b
ZOTA Zota Health Care	7x	n/a	₹15.4b

Price-To-Sales vs Peers: ZOTA is expensive based on its Price-To-Sales Ratio (7x) compared to the peer average (3.2x).

Price to Sales Ratio vs Industry

How does ZOTA's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

14 Companies	Price / Sales	Estimated Growth	Market Cap
NECLIFE Nectar Lifesciences	0.5x	n/a	US$90.51m
539561 Remedium Lifecare	0.07x	n/a	US$25.74m
524824 Bal Pharma	0.6x	n/a	US$22.94m
532637 Mangalam Drugs & Organics	0.5x	n/a	US$22.94m

14 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: ZOTA is expensive based on its Price-To-Sales Ratio (7x) compared to the Indian Pharmaceuticals industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is ZOTA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZOTA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ZOTA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.